Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial
Crossref DOI link: https://doi.org/10.1007/s40272-016-0184-2
Published Online: 2016-07-26
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Findling, Robert L.
Landbloom, Ronald L.
Mackle, Mary
Wu, Xiao
Snow-Adami, Linda
Chang, Kiki
Durgam, Suresh
Funding for this research was provided by:
Merck
Forest Laboratories
License valid from 2016-07-26